Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma

NCT04176380 is registered in ClinicalTrials.gov with Rapa Therapeutics LLC as lead sponsor.

NCT NCT04176380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma
Lead sponsor
Rapa Therapeutics LLC
Phase
Phase 2
Overall status
Completed
Start date
December 2, 2020
Completion date
June 6, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed, refractory multiple myeloma